Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review

Reratilwe Ephenia Mphahlele, Omolemo Kitchin, R Masekela

ABSTRACT

Objective To identify reasons for poor asthma control in African children and adolescents.

Design Systematic review

Data sources PubMed, Scopus, CINHAL, PsycINFO, MEDLINE and Web of Science databases were systematically searched up to 31 May 2020. Hand searching was done on Sabinet, African Journal online and Google Scholar.

Eligibility criteria Studies identifying barriers to asthma control, where asthma control was assessed by the validated Asthma Control Test/Child Asthma Control Test and/or Asthma Control Questionnaire were included.

Data extraction and synthesis Two reviewers independently selected studies for inclusion with disagreements resolved by a research team discussion, including a third reviewer. Data were extracted using the Cochrane Effective Practice and Organization of Care data collection form. The quality of the included studies was assessed using the modified Newcastle-Ottawa quality assessment scale. Identified barriers were reported in a thematic narrative synthesis.

Primary outcomes Poorly controlled asthma and associated factors.

Results From 914 records, three studies conducted between 2014 and 2019 in Nigeria, Uganda and South Africa met the inclusion criteria. A total of 883 children aged 4–19 years were analysed. Older age, concurrent allergy and city-dwelling significantly impacted asthma control. Few children with asthma symptoms in the community had ever used inhaled corticosteroids (6.7%) and identified reasons included lack of asthma diagnosis (38.8%) and no prescribed treatment (47.6%).

Conclusion Asthma control in African children is impacted by age, allergy, urbanisation and lack of access to asthma diagnosis and treatment. More studies focusing on identifying barriers to asthma control in Africa are needed.

INTRODUCTION

Asthma is a chronic non-communicable respiratory disease. According to the 2018 Global Asthma Report, asthma affects over 340 million people worldwide, the majority of whom reside in low-income and middle-income countries (LMICs). In contrast to many high-income countries (HICs), the prevalence of asthma is steadily increasing in LMICs, particularly in Africa. The latest systematic review on asthma prevalence in Africa shows that compared with 74 million in 1990, by 2010, asthma affected 119 million of the total population. Of concern, nearly half of these asthma cases were children under 15 years. Countries with the highest childhood asthma prevalence in Africa, South Africa (20.3%), Congo (19.9%) and Ivory Coast (19.3%), are also regions with increasing urbanisation rates. Factors associated with urbanisation including poverty, poor air quality and lifestyle and dietary changes may drive the rising asthma rate and impact asthma control. However, in this setting, access to asthma healthcare and diagnosis as well as asthma research and research infrastructure remains lacking.

The most commonly used validated tools for asthma control assessment are the composite score instruments: Asthma Control Test (ACT), Child Asthma Control Test (cACT) and the Asthma Control Questionnaire (ACQ). The ACT and ACQ provide a quantitative assessment of asthma control and have been designated as core measures by the National Institutes of Health (NIH) for clinical research and observational studies. ACT and ACQ are simple methods that can help quantify the impact of barriers on asthma control, which may not

To cite: Mphahlele RE, Kitchin O, Masekela R. Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review. BMJ Open 2021;11:e053100. doi:10.1136/bmjopen-2021-053100

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-053100).

Received 05 May 2021
Accepted 11 October 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

1Department of Paediatrics and Child Health, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa
2Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa

Correspondence to Dr Reratilwe Ephenia Mphahlele; mphahleler@ukzn.ac.za

Strength and limitations of this study

► This systematic review highlights the paucity of studies on barriers and determinants of asthma control in Africa.
► The sufficiently validated Asthma Control Test/Child Asthma Control Test was used to assess asthma outcomes and identify barriers to asthma control.
► Barriers to asthma control reported in this study contribute to, and match those described in the literature on paediatric asthma.
► A limitation of this study is that the heterogeneity of the studies precluded a meta-analysis.
be comparable between HICs and LMICs. This review was conducted to collate data on reported barriers to asthma control in children and adolescents in Africa.

METHODS

The systematic review is registered with PROSPERO (registration no: CRD42020196755). We used the Population, Exposure, Comparator and Outcomes (PECO) acronym to aid with the systematic search. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting standards were followed. The Synthesis Without Meta-Analysis reporting items guideline was used in conjunction with the PRISMA.

Search strategy

The following databases were searched: PubMed, Scopus, CINHAL, PsycINFO, MEDLINE and Web of Science. The search methodology for all the databases is provided in the supplementary material (online supplemental table 1). Hand searching of the following databases was also conducted: Sabinet, African Journal online and Google Scholar. Only scientific articles written in English with date restrictions from 1 January 2000 to 31 May 2020 were included.

The search strategy was structured to include terms for ‘Child’, ‘Asthma’, ‘Barriers’, ‘Asthma Control Test’, ‘Africa’ and/or variations of these.

Selection of studies

Studies identified from searching electronic databases were combined and duplicates were removed. Two reviewers (REM, OK) independently screened references using a three-stage review of title and abstract, followed by a full-text review of included studies. The full text of potentially eligible studies was screened against the review criteria and potential articles identified. At each stage, disagreements were resolved by a team discussion with a third reviewer (RM).

Inclusion and exclusion criteria

The study’s focus was to identify barriers associated with poor asthma control in African children and adolescents with doctor-diagnosed/suspected asthma, where the validated ACT/cACT or ACQ tool was used to assess asthma control. The population included children between the ages of 6 and 18 years. Studies were included with broader age ranges if children aged 6–18 years were reported separately, or if >50% of the population were children within this age range.

Studies published from January 2000 to May 2020 were included to ensure the encompassing of all data since validation of the ACT and ACQ. Clinical trials assessing pharmaceutical treatment and diagnostic accuracy of tools were excluded. Grey literature from experts in the field, conference abstracts or unpublished material were also excluded (table 1).

Data extraction

The full texts of all studies found to be relevant and meeting the inclusion criteria were retained for data extraction and final synthesis. Data including study design, setting, population, authorship and statistical analysis was extracted using a standardised data extraction form modified from the Cochrane Effective Practice and Organization of Care data collection form. The authors were contacted where clarification was required, and data were missing. The selection process was summarised using a PRISMA flow diagram (figure 1).

Quality assessment

The included studies’ quality was assessed using the modified Newcastle-Ottawa Scale for cohort, case studies and cross-sectional studies (online supplemental table 2).

Data analysis and synthesis

We anticipated that the population and statistical analysis heterogeneity of the studies would preclude a formal meta-analysis. We, therefore, grouped into themes asthma control barriers corresponding to literature; patient, environmental, healthcare/doctor-related factors and comorbidities. (online supplemental table 3). Statistical analyses were performed using MedCalc-Software, Ostend, Belgium; http://www.medcalc.org:2018.

Patient and public involvement

Patients and the public were not involved in the study design or conduction of the study.

RESULTS

Search results

There were 914 articles identified: 863 articles through electronic database searching (EBSCO host=27, PubMed=136, Web of Science=97, Scopus=603) and an additional 51 articles through hand searching (Google scholar=23, Sabinet=12, AJOL=16). The total number of articles found after duplicates were removed was 498. Of the 498 articles screened, 484 were excluded as they were not appropriate or did not relate to the study. The remaining 14 full articles were assessed for eligibility, and 11 articles were excluded for the following reasons: wrong age group=2, did not use ACT/ACQ=2, not original research=2, assessed impact rather than barriers of poor asthma control=5. Three studies met the inclusion criteria (figure 1).

Characteristics of the studies

All three studies conducted in Nigeria, South Africa and Uganda were cross-sectional; two hospital-based and one community-based. The sample size was smaller for hospital-based studies with 207 and 115 participants in Nigeria and South Africa, respectively, compared with the community-based study of 561 participants in Uganda. Publication dates ranged from 2014 to 2019. The ages of participants ranged from 4 to 19 years. Asthma diagnosis was based on doctor diagnosis guided by...
the Global Initiative on Asthma (GINA),\textsuperscript{19} and symptom screening by the International Study of Asthma and Allergies in Childhood questionnaire.\textsuperscript{21} One study adjusted for age, gender and concurrent allergy,\textsuperscript{21} while the rest did not report adjusting for potential confounders, reducing their quality score\textsuperscript{19 20} (online supplemental table 2). To recruit participants, two of the hospital-based studies used consecutive enrolment from a group of children attending asthma clinic.\textsuperscript{19 20} The community-based study derived participants from a large case–control study investigating risk factors of asthma in school going children\textsuperscript{21 22} (table 2).

**Assessment of asthma control**

All the studies measured asthma control using ACT and cACT. Scores were based on the cut-off point of >19 for controlled asthma and ≤ 19 for uncontrolled asthma. The prevalence of uncontrolled asthma in the Nigeria, South Africa and Uganda was 30.9%, 44.3% and 44.5% respectively.

**Thematic synthesis**

**Patient-related factors**

**Age**

Two studies assessed the impact of age on asthma control. The large community-based study showed that older age (13–17 years) was significantly associated with poorer asthma control (adjusted regression coefficient (95% confidence interval), p-value: (−1.07 (−1.20 to −0.94), p<0.0001).\textsuperscript{21} The exception was a small clinic cohort of moderate quality, which showed no association.\textsuperscript{20}

**Gender**

Two of the studies\textsuperscript{20 21} that examined gender showed no significant association with asthma control.

| Table 1 | Criteria for the search and rules devised to facilitate inclusion/exclusion criteria |
|---------|----------------------------------------------------------------------------------|
| **Search strategy** | **Definition** | **Rules** |
| **Population** | Children and adolescents between ages 6 and 18 years with a doctor diagnosis or a baseline prescription for asthma treatment or presumed diagnosis of asthma based on a history of recurrent wheeze. | Included: Studies with broader ranges of ages if children aged 6–18 were reported separately or if >50% of the population were children within this age range. Excluded: Studies in adults (>18 years). |
| **Exposure** | Environmental related factors: Pollution (indoor and outdoor), environmental tobacco smoke, mould, biomass fuels, pets, physical exercise, sedentary lifestyle, antibiotic use, paracetamol use, industrial combustion, respiratory infections. Patient-related factors: Attitudes, knowledge and perceptions, adherence, beliefs, inhaler technique, lifestyle, relationships, communication. Healthcare and doctor-related factors: Availability of treatment and healthcare facilities, doctor asthma knowledge, time spent on asthma education, availability of medications. Comorbidities: Allergic rhinitis, obesity, obstructive sleep apnoea. | Included: Studies aiming to identify exposures that had a quantifiable impact on asthma control. Excluded: Clinical trials assessing pharmaceutical treatments. Studies assessing the diagnostic accuracy of tools. Studies assessing the validity of tools. |
| **Comparison (if applicable)** | Usual care in people of the same age with well-controlled asthma | |
| **Outcome** | Asthma control measured using ACT/cACT and/or ACQ | Excluded: Studies using tools for measuring asthma control other than ACT/cACT and/or ACQ |
| **Timeframe** | 20 years between January 2000 and May 2020 | Excluded: Studies conducted before January 2000 and after May 2020 |
| **Setting** | Africa | Excluded: Studies not done in Africa |
| **Study** | Cohort, case–control, cross-sectional | Included: Studies identifying exposures that impact asthma control as measured by cACT/ACT and/or ACQ |

ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; cACT, Child Asthma Control Test.
Asthma medication use

Two studies\(^{20,21}\) examined the use and compliance of asthma medication. The study among school-going children\(^ {21}\) showed that the majority (73%) had never used inhaled asthma medications. Additionally, regular use of inhaled asthma medication in the last 12 months was inadequate for salbutamol (18.1%) and corticosteroid (6.7%) even though the majority (55.8%) had a doctor diagnosis of asthma. Although not significant, in the same cohort, children with poorly controlled asthma preferred regular use of (salbutamol and prednisone) tablets rather than inhaled salbutamol and corticosteroids.\(^ {21}\) Conversely, in the cohort of children attending asthma clinic,\(^ {20}\) good adherence to medications was seen in 82.6% of patients. In these doctor-diagnosed children, asthma control was significantly associated with good adherence to medication, where 37.9% and 62.1% of patients had uncontrolled asthma and controlled asthma, respectively (\(\chi^2=0.217, p=0.002\)).\(^ {20}\)

Ethnicity

There was no significant association between asthma control and ethnicity (\(\chi^2=3.22, p=0.359\)) in Black-African, Caucasian, mixed-ethnicity and Indian participants in South Africa.\(^ {20}\)

Environmental related factors

Two studies conducted in Uganda\(^ {21}\) and Nigeria\(^ {19}\) examined the effects of rural versus urban domicile on asthma control. The school-based Ugandan cohort showed that city residence in early life was associated with poor asthma control (−1.99 (−3.69 to –0.29), \(p=0.02\)).\(^ {21}\) In contrast the clinic-based cohort in Nigeria showed, although without significance, that within the rural community, more children with current allergies had better control of their asthma (85.7%) when compared with their urban counterparts (66.7%). Interestingly, the children who lived in rural areas without concurrent allergy had poorly controlled asthma (50.0%) compared with their urban counterparts (28.3%), Fisher’s exact test=2.076, \(p=0.17\), although this too was not significant.\(^ {19}\)

All three included studies considered the presence of asthma triggers in their participants' environments, but only the South African study examined these triggers in relation to asthma control. Common triggers included dust, cold air, physical exercise, fumes or air pollution, pollen, pets, smoking and biomass fuels (figure 2). In the South African cohort, home circumstances including dust, cockroach, carpet, pets, toys in bed and smoking were not found to be associated with asthma control.\(^ {20}\)

The use of biomass fuel was uncommon in South Africa.
| Author ref | Study type | Setting | Year of publication | Country of origin | Sample size | Age ranges (years) | Asthma definition | Asthma control definition | Recruitment | Exposures | Quality score | Reviewers comment |
|-----------|------------|---------|---------------------|-------------------|-------------|-------------------|-------------------|---------------------|--------------|------------|---------------|-------------------|
| Ayuk et al\(^1\(^9\) | Cross-sectional | Hospital | 2018 | Nigeria | 207 | 4–18 | Doctor diagnosis, GINA | ACT/cACT >19 controlled <19 uncontrolled | Consecutive enrolment for 1 year from a group of children attending the asthma clinic | Family size, socioeconomic status, urban vs rural dwelling, allergy status (by ISAAC), Triggers (particulate and non-particulate) | 7/10 | Author contacted for further information on participant numbers. |
| Garba et al\(^1\(^0\) | Cross-sectional | Hospital | 2014 | South Africa | 115 | 5–18 | Doctor diagnosis | ACT/cACT =25 (ACT)/27 (cACT) total control >19 well-controlled ≤19 uncontrolled 16–19 somewhat controlled <16 Poorly controlled | Consecutive enrolment for 4 months from a group of children attending the asthma clinic | Presence of a smoker at home, presence of pets, cockroaches, and use of biomass fuel, the child’s sleeping environment (dust, carpets, and soft toys in the bedroom), Compliance with medications and inhaler technique, Allergy status (by clinical examination) | 5/10 | Author contacted for further information on recruitment strategy, data analysis, and participant numbers. |
| Mpairwe et al\(^1\(^1\) | Cross-sectional | Community School | 2019 | Uganda | 561 | 5–17 | Screening ISAAC questionnaire | ACT/cACT >19 Well controlled 15–19 partly controlled <15 Poorly controlled | Recruitment from children with self-reported breathing problems at schools in an urban area | Age, sex, regular physical exercise as recommended by WHO, area of residence in first 5 years of life (rural, town or city), concurrent allergy, antimalarials | 10/10 | Describes participants as derived from a large case-control* study to investigate risk factors of asthma. |

* Mpairwe et al\(^2\(^2\).  

ACT, Asthma Control Test; cACT, Child Asthma Control Test; GINA, Global Initiative for Asthma; ISAAC, International Survey on Asthma and Atopy in Children; WHO, World Health Organisation.
(6.1%) compared with Nigeria (22.1%) and was not found to be significantly associated with asthma control ($\chi^2=6.202$, p=0.185).19 20

Healthcare and doctor-related factors
Only the field-based study in Uganda, reported the impact of healthcare-seeking behaviour on asthma control. In 553 children who reported treating their asthma in the last year, 26.8% reported having ever used inhaled asthma medications, and a similar proportion, 29.7% reported having ever used herbal remedies for asthma management. On enquiry about previous asthma assessments and follow-up, 73 (13.2 %) visited a health facility to monitor their asthma, 45 (8.2%) children had ever had a lung function test; 2 (0.4%) had ever used a peak flow metre as an asthma monitoring tool at home, and only 3 (0.5%) had a personal written asthma action plan.21 The reason for having never used inhaled asthma medication was investigated in 405 children and included inhaled asthma medications had never been prescribed for them (47.6%), never been diagnosed (38.8%), high cost of inhalers (4.5%), fear of side effects of inhalers (4.5%), alternative treatment with salbutamol or steroid tablets (1.4%) and non-medical treatment, that is, wrapping up in warm clothes and resting.21

Comorbidities
All three studies assessed children for allergic rhinitis, but only two19 21 in relation to asthma control. In the larger powered community-based study,21 children with concurrent allergic rhinitis were more likely to have lower asthma control scores (~1.33 (~2.28 to ~0.38), p=0.006), whereas no significant association was found between atopy and asthma control in the small cohort clinic-based study.19 However, in the latter study, children with current allergy had more emergency hospital visits due to asthma exacerbations ($\chi^2=10.09$ (df: 1) p=0.002; Spearman’s R=0.22, p=0.001).19

DISCUSSION
Older age, concurrent allergic rhinitis and early life urban residence are barriers similar to HICs and significantly impact asthma control in African children. Access to healthcare and appropriate asthma medication remains limited, with a minority of children with asthma symptoms ever having used inhaled corticosteroids (ICS).

Older age
Mpairwe et al22 found adolescents in Uganda have inadequate asthma control and outcomes. Similarly, the age group 12–17 years was more predictive of exacerbations than other age groups in a European cohort study using the General Practice Research Database.21 One reason for this can be explained by adolescent studies that show poor adherence compared with other age groups.24 Social stigma, forgetfulness and poor understanding of medication play a significant role in adherence and warrant further exploration.25 26

Concurrent allergic rhinitis
The Ugandan and Nigerian studies found that children with allergic rhinitis (AR) had less well-controlled asthma and were more likely to be hospitalised. Similarly, in a large UK retrospective cohort of 9522 children with asthma, the presence of AR significantly increased the likelihood of physician visits and more than doubled the likelihood of hospitalisation. Furthermore, drug use and costs were significantly higher among children with asthma and concurrent AR.27 Active search and recognition of AR when assessing children remain critical in comprehensive asthma management.

Rural versus urban residence
Studies in Africa show a decreasing gradient in asthma prevalence between urban and rural areas.28 29 In this context, biomass fuel exposure remains a significant contributor to inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease.30 31 Few studies in Africa have compared asthma control between rural and urban areas.19 21 32 33 Urban residence was significantly associated with poorly controlled asthma in Uganda, where asthma risk among schoolchildren21 was three times higher in children who in early life resided in cities rather than rural areas.22 Similarly, rural to urban migration appears to be an important determinant of the increasing prevalence of wheeze among school-going children in Latin American cities.34 35 Increasing asthma rates in urban settings could be related to overcrowding, reduction of exercise, poorer air quality and changes in lifestyle and diets.

Access to diagnosis and healthcare
Six out of 10 children attending healthcare institutions have good asthma control, while a similar number of undiagnosed children in the community have poorly controlled asthma.19–21 Even after a diagnosis of asthma, ICS use is limited in communities21 36 compared with clinic patients20 who once diagnosed, have significantly better...
asthma control. The preference of tablets (salbutamol and corticosteroids) over ICS may largely be explained by their quick relief and ease of administration combined with underlying suboptimal knowledge and asthma medications cost.39 30 Furthermore, traditional healers remain integral to medical care in communities due to local cultural practices and beliefs. There is a need to communicate asthma management strategies to communities in a culturally sensitive manner.32 37 Triggers including dust, air pollution, pollen, pets and smoking common across the globe, indicate the feasibility of a global checklist and the necessity of avoidance education.38

Strengths and limitations
We may not have identified all significant barriers that impact asthma control as other asthma control tools, that is, GINA and National Asthma Education Programme, were excluded because they are not as sufficiently validated as the ACT and ACQ.18 Nevertheless, we identified variables in each group classification for poor asthma control in current literature.13 Our wide-ranging search strategy found no non-English articles requiring exclusion. The studies’ heterogeneity in terms of outcome analysis and population precluded a meta-analysis; therefore, we reported all the factors within the emerging themes.

Implications for clinical practice, healthcare systems and policymakers
Strategies that improve medication access, including initiatives like the WHO Essential Medicines List, low-cost equipment like plastic spacers39 and implementing culturally appropriate educational programmes for healthcare workers and the public, remain vital.40 41

Implications for future research
Studies beyond healthcare institutions that include communities in identifying barriers and their impact on asthma control are needed in African children.

CONCLUSION
Asthma control barriers requiring focus in Africa are lack of accurate diagnosis, limited access to inhaled therapy, lack of asthma knowledge and poor air quality. Better education and advocacy through community-based public interventions are needed to improve African children’s asthma control and outcomes.

Acknowledgements
We thank Drs Vuyokazi Ntlantsana, Dickens Akena and Desmond Kuypieil for their advice in preparing this report.

Contributors
REM, OK and RM designed the study and the search strategy. REM performed the literature search. REM, OK and RM performed the screening. REM performed the data extraction and analysis. REM, OK and RM interpreted the results. REM wrote the manuscript. All authors reviewed and approved the final version of the manuscript. RM is the study guarantor.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
None declared.

Patient consent for publication
Not applicable.

REFERENCES
1 The Global Asthma Network [Internet]. The global asthma report 2018: global asthma network, 2018. Available: http://www.globalasthmanetwork.org
2 Adeloye D, Chan KY, Rudan I, et al. An estimate of asthma prevalence in Africa: a systematic analysis. Croat Med J 2013;54:519–31
3 Ait-Khaled N, Odhiambo J, Peares N, et al. Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International study of asthma and allergies in childhood phase III. Allergy 2007;62:247–58
4 United Nations, Department for Economic and Social Affairs, Population Division [Internet]. World urbanisation prospects 2018: highlights [ST/ESA/SER.A/421]. 2019. Available: https://population.un.org/wup/Publications/
5 Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy 2005;60:1357–60
6 Ehrlich RJ, Jordaan E, du Toit D, et al. Underrecognition and undertreatment of asthma in Cape town primary school children. S Afr Med J 1998;88:986–94
7 Ayuk A, Iloh K, Obumneme-Anyim I. Practice of asthma management among doctors in south-east Nigeria. Afr J Respir Med 2010;6:14–17
8 Masekela R, Zurba L, Gray D. Dealing with access to spirometry in Africa: a commentary on challenges and solutions. Int J Environ Res Public Health 2019;16:62
9 Musafrifi S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in sub-Saharan countries: the challenges. East Afr J Public Health 2011;8:161–3
10 Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549–56
11 Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 2012;129:S24–33
12 Baidio F. Failure in asthma control: reasons and consequences. Scientifica 2013;2013:1–15
13 Green R.J. Barriers to optimal control of asthma and allergic rhinitis in South Africa. Current Allergy & Clinical Immunology 2010;23:8–11
14 Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160
15 Campbell M, McKenzie J, Sowden A, et al. Synthesis without meta-analysis (swim) in systematic reviews: reporting guideline. BMJ 2020;368:m4880
16 Ecop.cochrane.org [Internet], Effective Practice and Organisation of Care (EPOC), EPOC resources for review authors. Cochrane, 2017. Available: https://epoc.cochrane.org/resources/epoc-resources-review-authors
17 Modesti PA, Rebolini G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 2016;11:e0147601.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs
Reratlewe Ephena Mphahlele http://orcid.org/0000-0002-3348-9004
R Masekela http://orcid.org/0000-0002-2006-1201
Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison. *Thorax* 1998;53:919–26.

29 Addo-Yobo EO, Custovic A, Taggart SC, et al. Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren. *Thorax* 1997;52:161–5.

30 Olaniyi T, Dalvie MA, Röösli M, et al. Asthma-Related outcomes associated with indoor air pollutants among schoolchildren from four informal settlements in two municipalities in the Western Cape Province of South Africa. *Indoor Air* 2019;29:89–100.

31 Torres-Duque C, Maldonado D, Pérez-Padilla R, et al. Biomass fuels and respiratory diseases: a review of the evidence. *Proc Am Thorac Soc* 2008;5:577–90.

32 Green RJ, Greenblatt MM, Pilt M, et al. Asthma management and perceptions in rural South Africa. *Ann Allergy Asthma Immunol* 2001;86:343–7.

33 Mosler G, Oyenuga V, Addo-Yobo E, et al. Achieving control of asthma in children in Africa (Acacia): protocol of an observational study of children’s lung health in six sub-Saharan African countries. *BMJ Open* 2020;10:e035885.

34 Rodriguez A, Vaca MG, Chico ME, et al. Rural to urban migration is associated with increased prevalence of childhood wheeze in a Latin-American City. *BMJ Open Respir Res* 2017;4:e000205.

35 Ponte EV, Lima A, Almeida PCA, et al. Rural to urban migration contributes to the high burden of asthma in the urban area. *Clin Respir J* 2019;13:580–6.

36 Amin S, Soliman M, McIvor A, et al. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. *Patient Prefer Adherence* 2020;14:541–51.

37 Semenya SS, Maroyi A. Plants used by Bapedi traditional healers to treat asthma and related symptoms in Limpopo Province, South Africa. *Evid Based Complement Alternat Med* 2018;2018:1–33.

38 Vernon MK, Wildlund I, Bell JA, et al. What do we know about asthma triggers? A review of the literature. *J Asthma* 2012;49:991–8.

39 Zar HJ, Asmus MJ, Wenading EG. A 500-ml plastic bottle: an effective spacer for children with asthma. *Pediatr Allergy Immunol* 2002;13:217–22.

40 Ndaruwka P, Chimbari MJ, Sibanda EN. Development of a framework for increasing asthma awareness in Chitungwiza, Zimbabwe. *Asthma Res Pract* 2019;5:4.

41 Mash B, Rhode H, Pather M, et al. Quality of asthma care: Western Cape Province, South Africa. *S Afr Med J* 2009;99:892-6.
Table S1 SEARCH STRINGS Asthma control barriers in African children.

**PUBMED SEARCH STRING**

| pediatric* or paediatric* or child* or kindergarten* or kindergarden* or "elementary school*" or schoolchild* or boy or boys or girl* or "middle school*" or pubescen* or juvenile* or teen* or youth* or "high school*" or adolesec* or pre-pubesc* or prepubesc*) OR (child* or adolesec* or pediat* or paediat* [Journal]) OR child[MeSH Terms] OR infant[MeSH Terms] OR adolescent[MeSH Terms] OR pediatrics[MeSH Terms] OR minors[MeSH Terms] AND 

| Asthma control test OR Asthma control questionnaire OR ACT OR ACQ OR asthma control surveys OR asthma control assessment tool OR ACQ composite score OR ACQ5 OR ACQ6 OR ACQ-PEF OR ACQ-wLF AND 

| Challenges OR Challenge OR Problem OR Problems barriers or Difficulties or Issues or Limitations or Obstacles OR predisposing factors OR enabling factors OR factors or precipitating factors OR reinforcing factors OR risk factors OR predictor or contributing factors or key factors or cause or correlation OR Factor, Risk OR Risk Factors, Risk OR Risk Factor OR Population at Risk OR Risk, Population at OR Populations at Risk OR Risk, Populations at OR Causality OR Causalities OR Multifactorial Causality OR Causalities, Multifactorial OR Causality, Multifactorial OR Causation, Multiple OR Multiplication OR Causation, Multiple OR Multiple Causation OR Reinforcing Factors OR Factor, Reinforcing OR Factors, Reinforcing OR Reinforcing Factor OR Causation OR Causations OR Enabling Factors OR Enabling Factor OR Factor, Enabling OR Factors, Enabling OR Predisposing Factors OR Factor, Predisposing OR Factors, Predisposing OR Predisposing Factor AND 

| "asthma"[MeSH Terms] OR asthma[Text Word]OR Wheeze [All Fields]])) AND ((("africa"[MeSH Terms] OR "africa"[All Fields]) OR ("africa south of the sahara"[MeSH Terms] OR "africa"[All Fields] AND "south"[All Fields] AND "sahara"[All Fields]) OR "africa south of the sahara"[All Fields] OR ("sub"[All Fields] AND "saharan"[All Fields]) OR "sub saharan africa"[All Fields] OR ("angola"[MeSH Terms] OR angola[All Fields]) OR ("benin"[MeSH Terms] OR "benin"[All Fields]) OR ("botswana"[MeSH Terms] OR "botswana"[All Fields]) OR ("burkina faso"[MeSH Terms] OR "burkina"[All Fields] AND "faso"[All Fields]) OR ("burundi"[MeSH Terms] OR "burundi"[All Fields]) OR ("cape verde"[MeSH Terms] OR ("cape"[All Fields] AND "verde"[All Fields]) OR ("cabo"[All Fields] AND "verde"[All Fields]) OR ("cameroon"[MeSH Terms] OR "cameroon"[All Fields]) OR ("central african republic"[MeSH Terms] OR ("central"[All Fields] AND "african"[All Fields] AND "republic"[All Fields]) OR "central african republic"[All Fields]) OR ("chad"[MeSH Terms] OR "chad"[All Fields]) OR ("comoros"[MeSH Terms] OR "comoros"[All Fields]) OR ("congo"[MeSH Terms] OR "congo"[All Fields]) OR ("cote d'ivoire"[MeSH Terms] OR ("cote"[All Fields] AND "d'ivoire"[All Fields]) OR ("cote d'ivoire"[All Fields])) OR ("democratic republic of the congo"[MeSH Terms] OR ("democratic"[All Fields] AND "republic"[All Fields] AND "congo"[All Fields]) OR ("democratic republic of the congo"[All Fields]) OR ("djibouti"[MeSH Terms] OR "djibouti"[All Fields]) OR ("egypt"[MeSH Terms] OR "egypt"[All Fields]) OR ("equatorial guinea"[MeSH Terms] OR ("equatorial"[All Fields] AND "guinea"[All Fields]) OR ("equatorial guinea"[All Fields] OR ("eritrea"[MeSH Terms] OR "eritrea"[All Fields]) OR ("etiopia"[MeSH Terms] OR "etiopia"[All Fields]) OR ("gabon"[MeSH Terms] OR "gabon"[All Fields]) OR ("gambia"[MeSH Terms] OR "gambia"[All Fields]) OR ("ghana"[MeSH Terms] OR "ghana"[All Fields]) OR ("guinea"[MeSH Terms] OR "guinea"[All Fields]) OR ("guinea-bissau"[MeSH Terms] OR "guinea-bissau"[All Fields]) OR ("guinea-bissau"[All Fields] OR ("guinea"[All Fields] AND "bissau"[All Fields]) OR ("guinea bissau"[All Fields]) OR ("kenya"[MeSH Terms] OR ("kenya"[All Fields])) OR ("lesotho"[MeSH Terms] OR "lesotho"[All Fields]) OR ("lesotho"[All Fields]) OR ("liberia"[MeSH Terms] OR ("liberia"[All Fields]) OR ("liberia"[All Fields]))))))
OR "libya"[All Fields] OR ("madagascar"[MeSH Terms] OR "madagascar"[All Fields]) OR
("malawi"[MeSH Terms] OR "malawi"[All Fields]) OR ("mali"[MeSH Terms] OR "mali"[All Fields])
OR ("mauritania"[MeSH Terms] OR "mauritania"[All Fields]) OR ("mauritius"[MeSH Terms] OR
"mauritius"[All Fields]) OR ("comoros"[MeSH Terms] OR "comoros"[All Fields] OR "mayotte"[All
Fields]) OR ("morocco"[MeSH Terms] OR "morocco"[All Fields]) OR ("mozambique"[MeSH Terms]
OR "mozambique"[All Fields]) OR ("namibia"[MeSH Terms] OR "namibia"[All Fields]) OR
("niger"[MeSH Terms] OR "niger"[All Fields]) OR ("nigeria"[MeSH Terms] OR "nigeria"[All Fields])
OR ("reunion"[MeSH Terms] OR "reunion"[All Fields]) OR ("rwanda"[MeSH Terms] OR
"rwanda"[All Fields]) OR ("atlantic islands"[MeSH Terms] OR ("atlantic"[All Fields] AND
"islands"[All Fields])) OR ("atlantic islands"[MeSH Terms] OR ("atlantic"[All Fields] AND
"islands"[All Fields])) OR ("saint helena"[All Fields] OR ("saint helena"[MeSH Terms] OR ("atlantic"[All Fields]
AND "islands"[All Fields])) OR ("atlantic islands"[All Fields] OR ("sao"[All Fields] AND "tome"[All
Fields] AND "principe"[All Fields]) OR "sao tome and principe"[All Fields]) OR ("senegal"[MeSH
Terms] OR "senegal"[All Fields]) OR ("seychelles"[MeSH Terms] OR "seychelles"[All Fields]) OR
("sierra leone"[MeSH Terms] OR ("sierra"[All Fields] AND "leone"[All Fields]) OR "sierra leone"[All
Fields]) OR ("somalia"[MeSH Terms] OR "somalia"[All Fields]) OR ("south africa"[MeSH Terms]
OR ("south"[All Fields] AND "africa"[All Fields]) OR ("south"[All Fields] AND "sudan"[All Fields])
OR "south sudan"[All Fields]) OR ("tanzania"[MeSH Terms] OR ("tanzania"[All Fields] OR "togo"[MeSH Terms]
OR "togo"[All Fields]) OR ("tunisia"[MeSH Terms] OR ("tunisia"[All Fields] OR "uganda"[MeSH Terms]
OR "uganda"[All Fields]) OR ("zambia"[MeSH Terms] OR "zambia"[All Fields]) OR
("zimbabwe"[MeSH Terms] OR "zimbabwe"[All Fields])
### SCOPUS SEARCH STRING

| Pediatric* OR paediatric* OR child* OR kindergarten* OR "elementary school*" | OR schoolchild* OR boy OR boys OR girl* OR "middle school*" OR pubescen* OR juvenile* OR teen* OR youth* OR "high school*" OR adolesc* OR pre-pubesc* OR prepubesc* OR child* OR adolesc* OR pediat* OR paediat* OR child OR adolescent OR pediatric* OR minor* |
|---|---|
| "Asthma*" OR "Bronchial Asthma" OR "Bronchial" AND "Asthma" OR "Bronchial Asthma, Exercise Induced" OR "Exercise Induced Bronchial Asthma*" OR "Asthma*, Exercise-Induced" OR "Exercise Induced Asthma" OR "Exercise-Induced Asthma*" OR "Bronchospasm, Exercise-Induced" OR "Bronchospasm*, Exercise Induced" OR "Exercise-Induced Bronchospasm*" |
| OR "Exercise Induced Bronchospasm" OR "Bronchial Spasm*" OR "Spasm*, Bronchial" OR "Bronchospasm*" OR "Wheez*" OR "Status Asthmaticus" OR "Bronchial Hyperreactivity*" |
| OR "Respiratory Hypersensitivity*" OR "Bronchoconstrict*" |
| AND |
| "Asthma control test*" OR "Asthma control questionnaire*" OR ACT OR "Childhood asthma control test*" OR C-ACT OR ACQ OR "asthma control survey*" OR "asthma control assessment tool*" OR "ACQ composite score" OR ACQ5 OR ACQ6 OR ACQ-PEF OR ACQ-wLF |
| AND |
| Challenge* OR Problem* OR Barriers OR Difficult* OR Issue* or Limitation* OR Obstacle* OR "predisposing factor*" OR "enabling factor*" OR factors OR "precipitating factor*" OR "reinforcing factor*" OR "risk factor*" OR predictor OR "contributing factor*" OR "key factor*" OR caus* OR correlation* OR "Factor, Risk" OR "Factors, Risk" OR "Risk Factor" OR "Risk, Population" at OR "Populations at Risk" OR "Risk, Populations at" OR Causalities OR "Multifactorial Causality" OR "Causality, Multifactorial" OR "Causality, Multi-factorial" |
| OR "Predisposing Factors" OR "Reinforcing Factors" OR "Factor, Reinforcing" OR "Enabling Factor*" OR "Factor, Enabling" OR "Factor*, Enabling" OR "Predisposing Factor*" OR "Factor, Predisposing*" |
| AND |
| "africa" OR "africa" OR "africa south of the sahara" OR "Africa AND south" AND "sahara" OR "africa south of the sahara" OR "sub AND saharan AND africa" OR "sub Saharan africa" OR "angola" OR "angola" OR "benin" OR "botswana" OR "botswana" OR "burkinafaso" OR "burkina AND faso" OR "burkinafaso" OR "burundi" OR "borneo" OR "cape verde" OR "cape AND verde" OR "cape verde" OR "cape verde" OR "cabo AND verde" OR "cabo verde" OR "cameroon" OR "central african republic" OR "central AND african AND republic" OR "central african republic" OR "chad" OR "comoros" OR "congo" OR "cote d'ivoire" OR "cote AND d'ivoire" OR "democratic republic of the congo" OR "democratic AND republic AND congo" OR "democratic republic of the congo" OR "djibouti" OR "egypt" OR "equatorial guinea" OR "equatorial AND guinea" OR "eritrea" OR "etiopia" OR "gabon" OR "gambia" OR "ghana" OR "guinea" OR "guinea-bissau" OR "guinea AND bissau" OR "guinea bissau" OR "kenya" OR "lesotho" OR "liberia" OR "libya" OR "madagascar" OR "malawi" OR "mali" OR "mauritania" OR "mauritius" OR "mayotte" OR "morocco" OR "mozambique" OR "namibia" OR "niger" OR "nigeria" OR "reunion" OR "rwanda" OR "atlantic islands" OR "atlantic AND islands" OR "saint AND helena" OR "saint helena" OR "sao AND tom e principe" OR "sao tome and principe" OR "senegal" OR "seychelles" OR "sierra leone" OR "sierra AND leone" OR "somalia" OR "south africa" OR "south AND africa" OR "south sudan" OR "south AND sudan" OR "swaziland" OR "tanzania" OR "togo" OR "tunisia" OR "uganda" OR "zambia" OR "zimbabwe"
Web of Science SEARCH STRING

| pediatric* OR paediatric* OR child* OR kindergarten* OR "elementary school*** OR schoolchild* OR boy OR boys OR girl* OR "middle school*** OR pubescent* OR juvenile* OR teen* OR youth* OR "high school*** OR adolesc* OR pre-pubescent* OR prepubesc* OR child* OR adolesc* OR pediat* OR paediat* OR child OR adolescent OR pediatrics OR minors
| "asthma" OR asthma OR Asthmatics OR Bronchial Asthma OR Asthma OR Bronchial Asthma, Exercise Induced OR Exercise-Induced Asthma OR Asthmatics, Exercise-Induced OR Exercise Induced Asthma OR Exercise-Induced Asthmatics OR Bronchospasm, Exercise-Induced OR Exercise-Induced Bronchospasms, Exercise-Induced OR Exercise-Induced Bronchospasms OR Exercise-Induced Bronchospasm OR Exercise Induced Bronchospasm OR Bronchial Spasms OR Spasm, Bronchial OR Spasms, Bronchial OR Bronchospasm OR Bronchospasms OR Wheeze OR Status Asthmatics OR Bronchial Hyperreactivity OR Respiratory Hypersensitivity OR Bronchoconstriction
| Asthma control test OR Asthma control questionnaire OR ACT OR Childhood asthma control test OR C-ACT OR ACQ, OR asthma control surveys OR asthma control assessment tool OR ACQ composite score OR ACQ5 OR ACQ6 OR ACQ-PEF OR ACQ-wLF
| Challenges OR Challenge OR Problem OR Problems or barriers or Difficulties OR Issues OR Limitations or Obstacles OR predisposing factors OR enabling factors OR factors or precipitating factors OR reinforcing factors OR risk factors OR predictor or contributing factors or key factors or cause or correlation OR Factor, Risk OR Factors, Risk OR Risk Factor OR Population at Risk OR Risk, Population at OR Populations at Risk OR Risk, Populations at OR Causality OR Causalities, Multifactorial OR Causality, Multifactorial OR Multifactorial Causality OR Multiple Causation OR Causation, Multiple OR Multiple Causations OR Reinforcing Factors OR Factor, Reinforcing OR Factors, Reinforcing OR Reinforcing Factor OR Causation OR Causations OR Enabling Factors OR Enabling Factor OR Factors, Enabling OR Predisposing Factors OR Factor, Predisposing OR Factors, Predisposing OR Predisposing Factor
| "africa" OR "africa" OR "africa south of the sahara" OR "africa" AND "south" AND "sahara" OR "africa south of the sahara" OR "sub" AND "saharan african" OR "sub saharanafrican" OR "angola" OR "angola" OR "benin" OR "benin" OR "botswana" OR "botswana" OR "burkinafaso" OR "burkina" AND "faso" OR "burkinafaso" OR "burundi" OR "cape verde" OR "cape" AND "verde" OR "cape verde" OR "cabo" AND "verde" OR "caboverde" OR "cameroon" OR "cameroon" OR "central african republic" OR "central" AND "african" OR "african" OR "central african republic" OR "chad" OR "chad" OR "comoros" OR "comoros" OR "congo" OR "congo" OR "cote d'ivoire" OR "cote" AND "d'ivoire" OR "cote d'ivoire" OR "democratic republic of the congo" OR "democratic" AND "republic" OR "democratic republic of the congo" OR "djibouti" OR "djibouti" OR "egypt" OR "egypt" OR "equatorial guinea" OR "equatorial" AND "guinea" OR "equatorial guinea" OR "eritrea" OR "eritrea" OR "etiopia" OR "etiopia" OR "gabon" OR "gabon" OR "gambia" OR "gambia" OR "ghana" OR "ghana" OR "guinea" OR "guinea" OR "guinea-bissau" OR "guinea-bissau" OR "guinea" AND "bissau" OR "guinea-bissau" OR "kenya" OR "kenya" OR "lesotho" OR "letho" OR "liberia" OR "liberia" OR "libya" OR "libya" OR "madagascar" OR "madagascar" OR "malawi" OR "malawi" OR "mali" OR "mali" OR "mauritania" OR "mauritania" OR "mauritius" OR "mauritius" OR "comoros" OR "comoros" OR "mayotte" OR "morocco" OR "morocco" OR "mozambique" OR "mozambique" OR "namibia" OR "namibia" OR "niger" OR "niger" OR "nigeria" OR "nigeria" OR "reunion" OR "reunion" OR "rwanda" OR "rwanda" OR "rwanda" OR "atlantic islands" OR "atlantic" AND "islands" OR "atlantic islands" OR "saint" AND "helena" OR "saint helena" OR "atlantic"
islands" OR "atlantic"AND "islands"OR "atlantic islands"OR "sao"AND "tome"AND "principe"OR "sao tome and principe"OR "senegal" OR "senegal"OR "seychelles" OR "seychelles"OR "sierra leone" OR "sierra"AND "leone"OR "sierra leone"OR "somalia" OR "somalia"OR "south africa" OR "south"AND "africa"OR "south africa"OR "south sudan" OR "south"AND "sudan"OR "south sudan"OR "sudan" OR "sudan"OR "swaziland" OR "swaziland"OR "tanzania" OR "tanzania"OR "togo" OR "togo"OR "tunisia" OR "tunisia"OR "uganda" OR "uganda"OR "zambia" OR "zambia"OR "zimbabwe" OR "zimbabwe"
EBSCO host: CINAHL Complete, Academic Search Complete, APA PsycInfo, CINAHL with Full Text, MEDLINE Complete, MEDLINE with Full Text) SEARCH STRING

```
[((pediatric* or paediatric* or child* or kindergarten* or "elementary school*" or schoolchild* or boy or boys or girl* or "middle school*" or pubescen* or juvenile* or teen* or youth* or "high school*" or adolesc* or pre-pubesc* or prepubesc*) OR (child* or adolesc* or paediat* or paediat* [Journal]) OR child[MeSH Terms] OR infant[MeSH Terms] OR adolescent[MeSH Terms] OR pediatrics[MeSH Terms] OR minors[MeSH Terms])) Search modes - Boolean/Phrase

AND

( environmental factors OR environmental influences OR environmental exposure ) OR ( environmental factors.mp. OR environmental influences.mp OR environmental exposure.mp. OR environmental tobacco smoke.mp. OR maternal smoking.mp. OR parental smoking.mp. OR Nitrogen Dioxide/ OR gas fire*.mp. OR cooker*.mp. mp. OR Volatile Organic Compounds/ OR cleaning agents.mp. OR chemicals.mp. OR glue*.mp. OR floor covering*.mp. OR dry cleaning.mp. OR Chlorine/ or swimming pool*.mp. resin*.mp. OR varnish.mp. OR Paint/ OR ethyl benzene.mp. OR air fresheners.mp. OR toluene.mp. OR caulk*.mp. / OR Vehicle Emissions/ae, pc, to [Adverse Effects, Prevention & Control, Toxicity] OR plastic$.mp. OR phthalate$.mp. OR flame retardant$.mp. OR plasticizer$.mp. OR plastici$.polyvinyl chloride.mp. OR floor covering$.mp. OR adhesive$.mp. OR synthetic leather.mp. OR toy$.mp. OR cosmetic$.mp. OR indoor dust.mp. OR di 2-ethylhexyl phthalate.mp. OR pvc.mp. OR outdoor source$.mp. OR ozone.mp. OR sulphur dioxide.mp. OR traffic.mp. OR exhaust.mp. OR coal fire$.mp. OR diesel.mp. OR weather.mp OR particulate matter.mp. OR UFPS.mp. OR transport.mp. OR industrial incineration.mp. OR firework$.mp. OR bonfire.mp. OR solid fuel.mp. OR heating$.mp. OR cooking.mp OR candle$.mp. OR vacuum$.mp. OR hoover$.mp. OR resuspension.mp. OR ingestion.mp. OR incineration.mp. OR NOX.mp. OR mp. OR carpet*.mp. OR tetraethyl lead.mp. OR cerium oxide*.mp. OR cold air.mp. OR meteorolog*.mp. OR. temperature.mp. OR climate.mp. OR air pollut*.mp. OR total suspended particulate*.mp. OR coal.mp. OR wood.mp. OR peat.mp. OR biomass.mp. OR oil.mp. OR diacetyl.mp. OR allergens.mp. OR aspergillus.mp. OR cladosporium.mp. OR dust mite*.mp. OR cat*.mp. OR dog*.mp. OR horse*.mp. OR animal*.mp. OR pet*.mp. OR mould.mp. OR alternaria.mp. OR cockroach*.mp. OR mice.mp. OR rats.mp. OR pollen.mp. OR grass.mp. OR aeroallergen*.mp. OR lge.mp. OR fungal spore*.mp. OR food allerg*.mp. OR glucan*.mp. OR peanut*.mp. OR egg.mp. OR milk.mp. OR dairy.mp. OR exercise.mp. OR 197. lipopolysaccharide.mp. OR endotoxin.mp. OR respiratory syncitial virus.mp. OR rhinovirus.mp. OR influenza virus.mp. OR corona virus.mp. OR diet.mp. OR sulphite*.mp. OR sulfite*.mp. OR sodium metabisul*.mp. OR mono sodium glutamate.mp. OR MSG.mp. OR sodium benzoate.mp. OR vitamin D.mp. OR vitamin E.mp. OR antioxidant*.mp. OR lipid*.mp. OR drug*.mp. OR aspirin.mp. OR paracetamol.mp. OR antibiotic*.mp. OR NSAID*.mp. OR NObesity.mp. ) OR ( Challenges OR Challenge OR Problem OR Problems barriers or Difficulties or Issues or Limitations or Obstacles OR predisposing factors OR enabling factors OR factors or precipitating factors OR reinforcing factors OR risk factors OR predictor or contributing factors or key factors or cause or correlation OR Factor, Risk OR Factors, Risk OR Population at Risk OR Risk, Population at OR Populations at Risk OR Risk, Populations at OR Causality OR Multifactorial OR Causality, Multifactorial OR Multifactorial Causality OR Multiple Causation OR Causation, Multiple OR Causations, Multiple OR Multiple Causations OR Reinforcing Factors OR Factor, Reinforcing OR Factors, Reinforcing OR Reinforcing Factor OR Causation OR Causations OR Enabling Factors OR Enabling Factor OR Factor, Enabling OR Factors, Enabling OR Predisposing Factors OR Factor, Predisposing OR Factors, Predisposing OR Predisposing Factor )

AND
```
Asthma control test OR Asthma control questionnaire OR ACT OR ACQ OR asthma control surveys OR asthma control assessment tool OR ACQ composite score OR ACQ5 OR ACQ6 OR ACQ-FEV1 OR ACQ-PEF OR ACQ-wLF

AND

(MH "Asthma") OR "asthma" OR (MH "Asthma, Occupational") OR (MH "Asthma, Exercise-Induced") OR (MH "Status Asthmaticus")

AND

(MM "Africa") OR "africa" OR (MH "Africa South of the Sahara") OR (MH "Africa, Western") OR (MH "Democratic Nursing Organisation of South Africa") OR (MH "Africa, Southern") OR (MH "Africa, Eastern") OR (MH "Africa, Northern") OR (MH "South Africa") OR (MH "Africa, Central") OR (MH "South African Nursing Council") OR (MH "Namibia") OR (MH "Yohimbe") OR (MH "Medicine, African Traditional") OR (MH "Guinea") OR (MH "Ghana") OR (MH "Gabon") OR (MH "Ethiopia") OR (MH "Eritrea") OR (MH "Equatorial Guinea") OR (MH "Egypt") OR (MH "Djibouti") OR (MH "Democratic Republic of the Congo") OR (MH "Cote d'Ivoire") OR (MH "Botswana") OR (MH "Burkina Faso") OR (MH "Burundi") OR (MH "Cameroon") OR (MH "Cape Verde") OR (MH "Central African Republic") OR (MH "Algeria") OR (MH "Benin")
Table S2 NEWCASTLE OTTAWA QUALITY ASSESSMENT of included studies. Taken from: PA Modesti et al., (2016). 17

| Selection: (Maximum 5 stars) | Ayuk et al. 2018 | Garba et al. 2014 | Mpairwe et al. 2019 |
|------------------------------|------------------|------------------|---------------------|
| 1) Representativeness of the sample: | ★ ★ ★ | ★ | ★ ★ ★ |
| a) Truly representative of the average in the target population. * (all subjects or random sampling) | ★ | ★ | ★ |
| b) Somewhat representative of the average in the target population. * (non-random sampling) | | | |
| c) Selected group of users. | | | |
| d) No description of the sampling strategy. | | | |
| 2) Sample size: | ★ | | ★ |
| a) Justified and satisfactory. * | | | |
| b) Not justified. | 0 | | 0 |
| 3) Non-respondents: | | | |
| a) Comparability between respondents and non-respondents' characteristics is established, and the response rate is satisfactory. * | | | |
| b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory. | 0 | 0 | |
| c) No description of the response rate or the characteristics of the responders and the non-responders. | | | 0 |
| 4) Ascertainment of the exposure (risk factor): | ★ ★ ★ | ★ ★ | ★ ★ ★ |
| a) Validated measurement tool. ** | ★ ★ | | ★ ★ |
| b) Non-validated measurement tool, but the tool is available or described. * | | | ★ |
| c) No description of the measurement tool. | | | |
| Comparability: (Maximum 2 stars) | | | |
| 1) The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled. | | | |
| a) The study controls for the most important factor (select one). * | 0 | 0 | ★ |
| b) The study controls for any additional factor. * | 0 | 0 | ★ |
| Outcome: (Maximum 3 stars) | | | |
| 1) Assessment of the outcome: | ★ ★ ★ | ★ ★ | ★ ★ ★ |
| a) Independent blind assessment. ** | ★ ★ | ★ ★ | ★ ★ ★ |
| b) Record linkage. ** | | | |
| c) Self-report. * | | | |
| d) No description. | | | |
| 2) Statistical test: | | | |
| a) The statistical test used to analyze the data is clearly described and appropriate, and the measurement of the association is presented, including confidence intervals and the probability level (p value). * | ★ | ★ | ★ |
| b) The statistical test is not appropriate, not described or incomplete. | | | |
| TOTAL | 7 | 5 | 10 |

17. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PloS one. 2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601
Table S3 Barriers that impact asthma control in African children

Key:

Notes on this table:
- The study data has been grouped into thematic factors with multiple barriers; therefore, studies appear multiple times.
- Within each thematic factor, the studies are listed by the study design, quality score, size and the barriers they present.
- Barriers are colour coded according to the key below

| Barriers associated with uncontrolled asthma |  |
| Barriers that have null effect |  |
| Complex or difficult to interpret |  |

Abbreviations

| abbreviations | definition |
|---------------|------------|
| y             | years      |
| F             | female     |
| M             | male       |
| SPT           | skin prick test |
| FeNo          | fractional exhaled nitric oxide |
| n             | number of children |
| x             | number with outcome |
| N             | number of children in population |
| OR            | odds ratio |
| AMD           | adjusted Mean difference |
| m             | missing |
| ICS           | inhaled bronchodilator |
| SABA          | short-acting beta-agonist |
| AR            | allergic rhinitis |
| ETS           | environmental tobacco smoke |
| CS            | cross-sectional |
| CA            | controlled asthma |
| UA            | uncontrolled asthma |
| ACT           | asthma control test |
| %             | percent    |
| Study ID, Design, Quality Score | Country, Sample Size, Ages | Effect measure | Barrier definition | Effect value | 95%CI or significance | Reference group or comparator | Analysis used | Adjustments or variables | Comments |
|-------------------------------|-----------------------------|----------------|-------------------|--------------|-----------------------|-------------------------------|--------------|-------------------------|----------|
| **Age**                      |                             |                |                   |              |                       |                               |              |                         |          |
| Mpairwe H 2019 CS 10/10       | Uganda N= 561 [m=8] S-12 y =338 13-17 y =214 Age 5-18 y | AMD 13 -17 y | -1.07             | -1.20 to -0.94 | P < 0.0001            | 5-12 y                       | Multivariate analysis | Sex, regular physical exercise as recommended by WHO, area of residence 1st 5 years of life (rural, town or city), concurrent allergy, |          |
| Garba 2014 CS 6/10            | South Africa N=115 15-18 y =23 10-14 y =54 Age 4-19 y | x/n (%) 15-18 y | 15.18 y 11(47.8%) UA vs 10.14y 25(46.3%) UA | NS           | 10-14 y               | $^2$ test                     | None          |                         |          |
| **Gender**                   |                             |                |                   |              |                       |                               |              |                         |          |
| Mpairwe H 2019 CS 10/10       | Uganda N=561 [m=8] F n=292 M n=261 Age 5-18 y | OR F | -0.54             | NS           | M                     | Multivariate analysis         | Age, regular physical exercise as recommended by WHO, area of residence 1st 5 years of life (rural, town or city), concurrent allergy, |          |
| Garba 2014 CS 6/10            | South Africa N=115 F n=56 M n=59 Age 4-19 y | x/n (%) F | F 36 (46.4%) UA vs M 25 (42.4%) UA | NS           | M                     | $^2$ test                     | None          |                         |          |
| **Asthma medication use**     |                             |                |                   |              |                       |                               |              |                         |          |
| Mpairwe H 2019 CS 10/10       | Uganda N=561 [m=8] CA n=307 UA n=246 Age 5-18 y | Inhaled SABA Yes 100 (18.1%) | 51 (16.6%) CA vs 49 (19.9%) UA | NS           | $^2$ test             | No information                |                           |                          |          |
|                             |                             | ICS Yes 27 (6.7%) | 22 (7.2%) CA vs 15 (6.10%) UA | NS           | No information        |                               |                           |                          |          |
|                             |                             | Steroid tablets Yes 149 (27.0%) | 86 (28.1%) CA vs 63 (25.6%) UA | NS           | No information        |                               |                           |                          |          |
|                             |                             | Neither salbutamol nor steroids Yes 225 (40.7%) | 153 (49.8%) CA vs 72 (22.6%) UA | <0.0001      | $^2$ test             | No information                |                           |                          |          |
|                             |                             |                                   |                   |              |                       |                               |              |                         |          |
| **Ethnicity**                |                             |                |                   |              |                       |                               |              |                         |          |
| Garba 2014 CS 6/10            | South Africa N=115 CA n=64 UA n=51 Age 4-19 | x/n (%) Black n= 99 (86.1%) Coloured n= 76.1% White n= 5 (4.3%) Asian n= 4 (3.5%) | Black race 53 (82.1%) CA vs Black race 46 (90.2%) UA | NS           | $^2$ test             | None             |                          |          |

Mphahlele RE, et al. BMJ Open 2021; 11:e053100. doi: 10.1136/bmjopen-2021-053100
| Study ID, Design, Quality Score | Country, Sample Size, Ages | Effect measure | Barrier definition | Effect value | 95%CI or significance | Reference group or comparator | Analysis used | Adjustments or variables | Comments |
|--------------------------------|---------------------------|---------------|-------------------|--------------|----------------------|-----------------------------|---------------|------------------------|----------|
| Mpairwe H 2019 CS 10/10        | Uganda N=561 [m=8] Rural n=71 Town n=433 City n=49 Ages 5-18y | OR            | City dwelling in the first five years of life | -1.99        | -3.69 to -0.29 p=0.02 | Rural residence             | Multivariate analysis | Age, sex, regular physical exercise as recommended by WHO, concurrent allergy | Mpairwe et al. notes that p-value = 0.06 was for town and city and p-value= 0.02 for city only. |
| Ayuk A 2018 CS 6/10            | Nigeria N=207 Urban n=178 Rural n=28 Ages 4-18y | x/n (%)       | Urban residence    | Urban S6 (31.4%) UA vs Rural 9 (32.1%) UA | NS | Rural residence | Fisher’s exact test | No information | None |
| Garba B 2014 CS 6/10           | South Africa N=115 CA n=64 UA n=51 Age 4-19 | x/n (%)       | Dust n= 46 (40%)  | 25 (54.3%) CA vs 21 (45.7%) UA | NS |         | χ² test | None | None |
|                               |                           |              | Cockroach n= 39 (33.9%) | 19 (48.7%) CA vs 20 (53.1%) UA | NS |         | χ² test | None | None |
|                               |                           |              | Carpet n= 38 (33.0%) | 17 (44.7%) CA vs 21 (55.3%) UA | NS |         | χ² test | None | None |
|                               |                           |              | Pets n=26 (22.6%) | 15 (57.7%) CA vs 11 (42.3%) UA | NS |         | χ² test | None | None |
|                               |                           |              | Toys in bed n= 20 (17.4%) | 9 (45.0%) CA vs 110 (55.0%) UA | NS |         | χ² test | None | None |
|                               |                           |              | ETS n= 13 (11.3%) | 6 (46.2%) CA vs 7 (53.8%) UA | NS |         | χ² test | None | None |
| Study ID, Design, Quality Score | Country, Sample Size, Ages | Effect measure | Barrier definition | Effect value | 95%CI or significance | Reference group or comparator | Analysis used | Adjustments or variables | Comments |
|--------------------------------|---------------------------|---------------|-------------------|-------------|-----------------------|-------------------------------|----------------|--------------------------|----------|
| **Access to medication**       |                           |               |                   |             |                       |                               |                |                          |          |
| Mpairwe H 2019 CS 10/10         | Uganda N= 561 [m=8] CA n=307 UA n=246 Age 5-18 y | x/n (%)         | ICS Yes n=37 (6.7%) | 22 (7.2%) CA vs 15 (6.10%) UA | NS                      | Well-controlled asthma          | χ²test       | No information           |          |
| Mpairwe H 2019 CS 10/10         | Uganda N= 561 [m=8] CA n=307 UA n=246 Age 5-18 y | x/n (%)         | Inhaled SABA Yes n=100 (18.1%) | 51 (36.6%) CA vs 49 (19.9%) UA | NS                      | Well-controlled asthma          | χ²test       | No information           |          |
| Mpairwe H 2019 CS 10/10         | Uganda N= 561 [m=8] CA n=307 UA n=246 Age 5-18 y | x/n (%)         | Neither salbutamol nor steroids Yes n=225 (40.7%) | 153 (49.8%) CA vs 72 (29.3%) UA | p < 0.0001              | Well controlled asthma          | χ²test       | No information           | Mpairwe et al. noted that of 307 children with well-controlled asthma, 153 (49.8%) reported not using salbutamol or steroids in any formulation, they suggested that perhaps they had mild asthma. |
| **Skin prick test**            |                           |               |                   |             |                       |                               |                |                          |          |
| Mpairwe H 2019 CS 10/10         | Uganda N= 561 [m=8] ACT test scores N=553 [m=9] Negative n=244 Positive n=300 Ages 5-18y | OR              | Positive SPT ≥3mm  | -0.51         | -1.31 to 0.29 NS      | Negative SPT <3mm              | multivariate analysis | Age, sex, regular physical exercise as recommended by WHO, area of residence 1st 5 years of life (rural, town or city), concurrent allergy |          |
| **Fractional nitric oxide**     |                           |               |                   |             |                       |                               |                |                          |          |
| Mpairwe H 2019 CS 10/13         | Uganda N= 561 ACT test scores N=553 [m=13] Normal n=335 Elevated n=195 Ages 5-18y | OR              | Elevated value FeNo ≥ 35ppb | 0.42          | -0.39 to 1.24 NS      | Normal value FeNo <35ppb       | multivariate analysis | Age, sex, regular physical exercise as recommended by WHO, area of residence 1st 5 years of life (rural, town or city), concurrent allergy |          |
| Study ID, Design, Quality Score | Country, Sample Size, Ages | Effect measure | Barrier definition | Effect value | 95% CI or significance | Reference group or comparator | Analysis used | Adjustments or variables | Comments |
|-------------------------------|---------------------------|----------------|-------------------|--------------|------------------------|-----------------------------|---------------|------------------------|----------|
| Allergy                       |                           |                |                   |              |                        |                             |               |                        |          |
| Mpairwe H 2019 CS 10/10       | Uganda                    | OR             | Concurrent AR     | -1.33        | -2.28 to -0.38         | p = 0.006                   | No concurrent allergy       | multivariate analysis | Age, sex, regular physical exercise as recommended by WHO, area of residence 1st 5 years of life (rural, town or city) |
| Ayuk A 2018 CS 6/10           | Nigeria                   | x/n (%)        | Current allergy   | Current allergy 26 (30.2%) UA vs No Allergy 38 (31.4%) UA | NS | No current allergy | Fisher's exact test | No information |          |